Table 2.
Descriptive comparison between studies considered
| Source | Study design | Country | Sample (n) | Duration (wk) | Daily average dose (mg) | Change in assessment score |
|---|---|---|---|---|---|---|
| Tollefson et al. [38], 1998 | Post-hoc analysis of an RCT | USA Canada |
OLZ (198) HAL (69) PLC (68) |
6 | OLZ = 2.5−7.5 HAL = 10−20 |
OLZ 10 mg and 15 mg superior to PLC for BPRS, HAL no superior to PLC |
| Davis and Chen [36], 2001 | Post-hoc analysis of an RCT | USA Canada |
OLZ (1,987) HAL (809) PLC (118) |
6 | OLZ = 1−20 HAL = 5−20 |
OLZ superior to HAL for BPRS and PANSS |
| Conley and Mahmoud [42], 2001 | RCT | USA | OLZ (189) RIS (188) |
8 | OLZ =12 RIS = 5 |
RIS superior to OLZ for PANSS |
| Jeste et al. [43], 2004 | RCT | USA Israel Poland Norway Netherlands Austria |
OLZ (88) RIS (87) |
8 | OLZ = 10 RIS = 2 |
OLZ no different from RIS for PANSS |
| Lindenmayer et al. [40], 2004 | Post-hoc analysis of an RCT | USA | OLZ (39) CLZ (40) RIS (41) HAL (37) |
14 | OLZ = 10−40 CLZ = 200−800 RIS = 4−16 HAL = 10−30 |
OLZ, CLZ, RIS superior to HAL for PANSS |
| Ascher-Svanum et al. [37], 2005 | Post-hoc analysis of an RCT | International, conducted in 17 countries | OLZ (1,337) HAL (659) |
6 | OLZ = 13 HAL= 12 |
OLZ superior to HAL for BPRS |
| Wang et al. [41], 2006 | RCT | USA | OLZ (17) RIS (19) |
16−17.7 | OLZ = 15 RIS = 5 |
RIS superior to OLZ for PANSS |
RCT, randomized controlled trial; OLZ, olanzapine; HAL, haloperidol; RIS, risperidone; PLC, placebo; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale.